ARS PHARMACEUTICALS I

14,37

26-ноября-24 16:45:00

15 мин. задержка

Акции

+0,66

+4,81%

Сегодняшний диапазон

13,62 - 14,45

ISIN

N/A

Источник

NASDAQ

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

13 ноя 2024 06:30:01 Источник Nasdaq GlobeNewswire
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

11 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire
ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences

06 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

24 окт 2024 08:30:00 Источник Nasdaq GlobeNewswire
ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

23 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

10 сен 2024 16:05:00 Источник Nasdaq GlobeNewswire
ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)

09 сен 2024 16:47:16 Источник Nasdaq GlobeNewswire
ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

04 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire
EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

26 авг 2024 09:29:15 Источник Nasdaq GlobeNewswire
ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

09 авг 2024 12:49:53 Источник Nasdaq GlobeNewswire
ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference

07 авг 2024 09:01:10 Источник Nasdaq GlobeNewswire
ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results

06 авг 2024 16:01:00 Источник Nasdaq GlobeNewswire
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)

28 июн 2024 06:30:00 Источник Nasdaq GlobeNewswire
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results

09 май 2024 16:05:00 Источник Nasdaq GlobeNewswire
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand

30 апр 2024 09:01:00 Источник Nasdaq GlobeNewswire
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)

03 апр 2024 09:01:00 Источник Nasdaq GlobeNewswire
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

21 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day

07 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024

06 мар 2024 09:01:00 Источник Nasdaq GlobeNewswire
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

26 фев 2024 09:01:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.